http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007089774-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0ee509fca8f7a3259e7debf52effe63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a2f32f7f18ebcbcf8a3b9ca3850f0d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f66ef616918e707589c32a807ed0ed8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64668d8abe6c38a6931e9335b0bda4a1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2007-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1000b35bda006c55ca8115c4ba531d3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30606cbc49a175930fa8884c00b9ceec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13a566e919f4d1528d3bc1c41d743a7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4560b459842e1a743c6ee82f34108a01 |
| publicationDate | 2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007089774-A3 |
| titleOfInvention | Compositions and methods for treating cognitive disorders |
| abstract | The present invention relates to the use of inhibitors or blockers of Ih (hyperpolarization-activated cationic current) channels in the treatment of cognitive disorders. In preferred aspects of the present invention, an effective amount of a compound is administered to a patient in need, wherein the compound has the chemical structure (I) where R1 is H, or an optionally substituted C1-C3 alkyl, preferably a C2 alkyl (ethyl) group; R2 is an optionally substituted C1-C3 alkyl group, preferably a methyl group; R3 is H, an optionally substitutedC1-C3 alkyl (preferably methyl), a halogen or 0(Ci-Ca) alkyl; R4 is an optionally substituted C1-C6 alkyl, C(O)-(C1-C5)alkyl, C(O)-aryl, C(O)O-(C1- C4)alkyl, C(O)O-aryl, or an optionally substituted heterocyclic, aryl or heteroaryl group; R4ais H or an optionally substituted C1-C6 (preferably a C1-C3) alkyl; R5, R6 and R7 are each independently H, halogen, an optionally substituted C1-C6 alkyl (preferably, an optionally substituted C1-C3 alkyl), 0-(C1-C3) alkyl, or an optionally substituted heterocyclic, aryl or heteroaryl group; Y- is an anion of a pharmaceutically acceptable salt (a physiologically acceptable anion, preferably a Cl-, Br-, I-, OAc-); or a solvate or polymorph thereof, optionally, in combination with guanfacine and/or chelerythrine, and a pharmaceutically acceptable carrier, additive or excipient to a patient in need of therapy. |
| priorityDate | 2006-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.